144 related articles for article (PubMed ID: 1510701)
1. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel.
Savi P; Herbert JM; Pflieger AM; Dol F; Delebassee D; Combalbert J; Defreyn G; Maffrand JP
Biochem Pharmacol; 1992 Aug; 44(3):527-32. PubMed ID: 1510701
[TBL] [Abstract][Full Text] [Related]
2. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro.
Weber AA; Reimann S; Schrör K
Br J Pharmacol; 1999 Jan; 126(2):415-20. PubMed ID: 10077233
[TBL] [Abstract][Full Text] [Related]
3. The antiaggregating activity of clopidogrel is not affected by N-acetyl L-cysteine.
Lalé A; Herbert JM; Savi P
Thromb Haemost; 2003 Nov; 90(5):839-43. PubMed ID: 14597979
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of vascular ectonucleotidase activities by the pro-drugs ticlopidine and clopidogrel favours platelet aggregation.
Lecka J; Rana MS; Sévigny J
Br J Pharmacol; 2010 Nov; 161(5):1150-60. PubMed ID: 20977463
[TBL] [Abstract][Full Text] [Related]
5. The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat and in man.
Gachet C; Stierlé A; Cazenave JP; Ohlmann P; Lanza F; Bouloux C; Maffrand JP
Biochem Pharmacol; 1990 Jul; 40(2):229-38. PubMed ID: 2375765
[TBL] [Abstract][Full Text] [Related]
6. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.
Farid NA; Kurihara A; Wrighton SA
J Clin Pharmacol; 2010 Feb; 50(2):126-42. PubMed ID: 19948947
[TBL] [Abstract][Full Text] [Related]
7. Identification and biological activity of the active metabolite of clopidogrel.
Savi P; Pereillo JM; Uzabiaga MF; Combalbert J; Picard C; Maffrand JP; Pascal M; Herbert JM
Thromb Haemost; 2000 Nov; 84(5):891-6. PubMed ID: 11127873
[TBL] [Abstract][Full Text] [Related]
8. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
Payne CD; Li YG; Small DS; Ernest CS; Farid NA; Jakubowski JA; Brandt JT; Salazar DE; Winters KJ
J Cardiovasc Pharmacol; 2007 Nov; 50(5):555-62. PubMed ID: 18030066
[TBL] [Abstract][Full Text] [Related]
9. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A.
Savi P; Combalbert J; Gaich C; Rouchon MC; Maffrand JP; Berger Y; Herbert JM
Thromb Haemost; 1994 Aug; 72(2):313-7. PubMed ID: 7831671
[TBL] [Abstract][Full Text] [Related]
10. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention.
Sibbing D; von Beckerath O; Schömig A; Kastrati A; von Beckerath N
Am J Cardiol; 2007 Jul; 100(2):203-5. PubMed ID: 17631070
[TBL] [Abstract][Full Text] [Related]
11. Comparison between the antiaggregating effect of ticlopidine in whole blood, platelet-rich plasma and washed platelets of the rat.
Randon J; Lefort J; Vargaftig BB
Thromb Res; 1982 Apr; 26(1):13-20. PubMed ID: 7048623
[TBL] [Abstract][Full Text] [Related]
12. P2Y12, a new platelet ADP receptor, target of clopidogrel.
Herbert JM; Savi P
Semin Vasc Med; 2003 May; 3(2):113-22. PubMed ID: 15199474
[TBL] [Abstract][Full Text] [Related]
13. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial.
von Beckerath N; Taubert D; Pogatsa-Murray G; Schömig E; Kastrati A; Schömig A
Circulation; 2005 Nov; 112(19):2946-50. PubMed ID: 16260639
[TBL] [Abstract][Full Text] [Related]
14. [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].
Morel O; Viellard C; Faure A; Jesel L; Ohlmann P; Desprez D; Chauvin M; Roul G; Grunebaum L; Bareiss P
Ann Cardiol Angeiol (Paris); 2007 Jan; 56(1):21-9. PubMed ID: 17343035
[TBL] [Abstract][Full Text] [Related]
15. Clopidogrel pharmacodynamics and pharmacokinetics in the fed and fasted state: a randomized crossover study of healthy men.
Hurbin F; Boulenc X; Daskalakis N; Farenc C; Taylor T; Bonneau D; Lacreta F; Cheng S; Sultan E
J Clin Pharmacol; 2012 Oct; 52(10):1506-15. PubMed ID: 22128201
[TBL] [Abstract][Full Text] [Related]
16. Measurement of platelet aggregation during antiplatelet therapy in ischemic stroke.
Pongrácz E
Clin Hemorheol Microcirc; 2004; 30(3-4):237-42. PubMed ID: 15258349
[TBL] [Abstract][Full Text] [Related]
17. Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel.
Lordkipanidzé M; Pharand C; Palisaitis DA; Schampaert E; Diodati JG
Thromb Res; 2009 Nov; 124(5):546-53. PubMed ID: 19419755
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms.
Chen BL; Zhang W; Li Q; Li YL; He YJ; Fan L; Wang LS; Liu ZQ; Zhou HH
Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):904-8. PubMed ID: 18346178
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction.
Matetzky S; Fefer P; Shenkman B; Varon D; Savion N; Hod H
Am J Cardiol; 2008 Sep; 102(5):524-9. PubMed ID: 18721506
[TBL] [Abstract][Full Text] [Related]
20. Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.
Wong PC; Crain EJ; Watson CA; Hua J; Schumacher WA; Rehfuss R
Thromb Haemost; 2009 Jan; 101(1):108-15. PubMed ID: 19132196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
